Effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate on some proteins related to haemostasis in prostatic carcinoma patients

• Published in: International urology and nephrology Vol. 23; no. 3; p. 251
• Main Authors: Damber, J E, Daehlin, L, Tomic, R, Nilsson, T K
• Format: Journal Article
• Language: English
• Published: Netherlands 01.05.1991
• Subjects: Aged; Blood Coagulation Factors - drug effects; Blood Proteins - drug effects; Estradiol - analogs & derivatives; Estradiol - therapeutic use; Estradiol Congeners - therapeutic use; Estramustine - therapeutic use; Ethinyl Estradiol - therapeutic use; Hemostasis - physiology; Humans; Male; Orchiectomy; Prostatic Neoplasms - blood; Prostatic Neoplasms - therapy
• ISSN: 0301-1623
• DOI: 10.1007/BF02550420

Twenty-four previously untreated patients with carcinoma of the prostate were prospectively randomized to one of the following treatments: (1) ethinyl oestradiol combined with polyoestradiol phosphate (EE/EP); (2) estramustine phosphate (EM); (3) bilateral orchiectomy. The effects on some plasma proteins related to haemostasis were studied by measuring the concentrations of alpha-1-antitrypsin, orosomucoid, haptoglobin, antithrombin III, C1-inhibitor and von Willebrand's factor before and 3 months after the start of treatment. Orchiectomy induced a reduction of alpha-1-antitrypsin and haptoglobin, while the other studied proteins were unaffected. It was found that both EE/EP and EM treatment induced significant decreases of orosomucoid, haptoglobin, antithrombin III and C1-inhibitor, while the same treatment increased the plasma concentration of alpha-1-antitrypsin. None of these treatments showed any influence on the plasma concentration of the von Willebrand factor. No differences were observed between EE/EP and EM for any of the studied proteins, suggesting comparable oestrogenic effects of these forms of treatment in patients with prostatic carcinoma. The findings are discussed in relation to the proposed difference in thromboembolic complications between EE/EP and EM treatments of prostatic carcinoma patients.